Fig 1: DDR-related cytokines derived from glioma cells are synergistic with DDR alterations in vitro and in vivo.(a) Gene expression profiling revealed the associations between DDR-related cytokines and the DDR scores or DDR genes. (b) IHC assays were used to detect the expression level of six cytokines, C5, SAA1, MDK, IL6, VEGFA and TNFSF4 in glioma samples within the different DDR clusters (20×). (c) Western blot validation of DDR-associated protein and cytokine expression levels in LN229, LN229R, HG7, HG7R, GL261 and GL261R cells. (d) ELISA assay revealed differential expression of six cytokines in the medium of LN229, LN229R, HG7, HG7R, GL261 and GL261R cells. (e) Cytokine expression in xenograft gliomas formed by GL261 and GL261R cells was detected by IHC assays (20×).
Fig 2: ROC curves of serum OX40L in predicting SRA in asthma patients. The AUC was 0.733. A cutoff value of VDBP is 780 pg/mL, which can discriminate SRA from SSA among asthma patients, with 58.5% sensitivity and 86.4% specificity. ROC: receiver operating characteristics; AUC: area under the curve
Fig 3: Comparison of serum OX40L level in control, SSA and SRA groups. The serum level of OX40L (mg/ml) are significantly increased in SRA group than in SSA and control groups. ***P < 0.001) vs control group; ### P < 0.001 vs SSA group. SSA: steroid-sensitive asthma; SRA: steroid-resistant asthma
Fig 4: The change of serum OX40L level after ICS therapy in SSA (a) and SRA (b) asthmatic patients. c The reduction in serum OX40L after ICS treatment was compared between SSA group and SRA group. **P < 0.01; ***P < 0.001. SSA: steroid-sensitive asthma; SRA: steroid-resistant asthma
Supplier Page from Abcam for Human TNFSF4 ELISA Kit (OX40L)